Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Colin J. McKay

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1642-0782; OpenAlex author ID A5078953569, A5109250667. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
138
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 3 papers · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 6 papers · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 32

  1. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  2. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Co-author DOI 10.1093/bjs/znag032↗
  3. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  4. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  5. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  6. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  7. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  8. PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. Co-author DOI 10.1016/j.clon.2019.07.011↗
  9. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  10. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  11. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  12. Personalized Pancreatic Cancer Management: A Systematic Review of How Machine Learning Is Supporting Decision-making. Last author DOI 10.1097/mpa.0000000000001312↗
  13. A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer. Last author DOI 10.1136/bmjopen-2018-027192↗
  14. A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0222270↗
  15. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Co-author DOI 10.21037/cco.2019.04.06↗
  16. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  17. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  18. The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Co-author DOI 10.21037/jgo.2017.04.01↗
  19. RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Co-author DOI 10.1093/jnci/djv204↗
  20. SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. Co-author DOI 10.1371/journal.pone.0131344↗
  21. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
  22. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  23. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Co-author DOI 10.18632/oncotarget.2519↗
  24. The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11605-012-2131-z↗
  25. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s11605-013-2168-7↗
  26. Exploiting inflammation for therapeutic gain in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.24↗
  27. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarc… Co-author DOI 10.1158/1078-0432.ccr-11-0679↗
  28. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-012-2370-y↗
  29. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s11605-010-1395-4↗
  30. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e3182218ffb↗
  31. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Co-author DOI 10.1158/1078-0432.ccr-10-3284↗
  32. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ducta… Co-author DOI 10.1245/s10434-011-1560-3↗

Closest collaborators

The 25 strongest of 138 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nigel Balfour Jamieson · 23 shared papers, 2011–2026 · strength 1.66
  2. Stephan B. Dreyer · 6 shared papers, 2019–2026 · strength 0.90
  3. David Kuang-Fu Chang · 8 shared papers, 2014–2026 · strength 0.88
  4. Andrew Victor Biankin · 8 shared papers, 2014–2026 · strength 0.88
  5. C. Ross Carter · 12 shared papers, 2011–2020 · strength 0.54
  6. Fieke E. M. Froeling · 2 shared papers, 2026 · strength 0.49
  7. Alison Bradley · 3 shared papers, 2019 · strength 0.48
  8. Robert Van Der Meer · 3 shared papers, 2019 · strength 0.48
  9. Karin A. Oien · 10 shared papers, 2011–2022 · strength 0.45
  10. Jaswinder Singh Samra · 4 shared papers, 2019–2023 · strength 0.39
  11. Alessandra Pulvirenti · 2 shared papers, 2023–2026 · strength 0.35
  12. Antonio Pea · 2 shared papers, 2023–2026 · strength 0.35
  13. Rita Teresa Lawlor · 2 shared papers, 2023–2026 · strength 0.35
  14. Aldo Scarpa Scarpa · 2 shared papers, 2023–2026 · strength 0.35
  15. Roberto Salvia · 2 shared papers, 2023–2026 · strength 0.35
  16. Anthony James Gill · 3 shared papers, 2020–2023 · strength 0.33
  17. Jennifer P. Morton · 6 shared papers, 2012–2022 · strength 0.30
  18. Owen James Sansom · 6 shared papers, 2012–2022 · strength 0.30
  19. Adam S. Bryce · 1 shared paper, 2026 · strength 0.27
  20. Thomas R. Jeffry Evans · 4 shared papers, 2012–2022 · strength 0.22
  21. David K. Chang · 1 shared paper, 2026 · strength 0.22
  22. Claudio Luchini · 1 shared paper, 2026 · strength 0.22
  23. Amber L. Johns · 2 shared papers, 2020–2023 · strength 0.21
  24. Colin William Steele · 4 shared papers, 2011–2015 · strength 0.17
  25. Asif Ali · 2 shared papers, 2012–2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.